Helix BioPharma Files Q3 2025 Financials, Advances Innovative Cancer Pipeline

Helix BioPharma Corp., a clinical-stage oncology company trading on multiple exchanges including TSX (HBP), OTC PINK (HBPCD), and FRANKFURT (HBP0), has announced the filing of its unaudited interim financial statements for the three-month period ending October 31, 2025. The comprehensive Interim Filings package includes not only the Financial Statements but also the management's discussion and analysis (MD&A) and certifications from both the Chief Executive Officer and Chief Financial Officer. These critical documents are now publicly accessible through the Company's profile on the SEDAR+ platform at www.sedarplus.ca and directly on Helix's corporate website, providing investors and stakeholders with transparent insight into the company's financial health and strategic direction during this pivotal period of clinical development.

At the heart of Helix BioPharma's mission lies its innovative oncology pipeline, spearheaded by the promising Tumor Defense Breaker™ L-DOS47. This clinical-stage antibody-enzyme conjugate represents a novel approach to treating hard-to-treat cancers by targeting CEACAM6-expressing tumors to enhance their sensitivity to existing anti-cancer therapies. The company's research extends beyond L-DOS47, which has already completed Phase Ib studies in non-small cell lung cancer, to include next-generation bi-specific antibody-drug conjugates sharing the same CEACAM6-targeting foundation. Additionally, Helix is advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator designed to address post-transplant leukemia relapse, and GEMCEDA™, a groundbreaking oral gemcitabine prodrug offering bioavailability comparable to intravenous administration, potentially expanding treatment options for patients with advanced cancers.

The company's forward-looking statements emphasize both the potential of their innovative pipeline and the inherent uncertainties of drug development, reminding investors that actual results may differ from projections. These statements reference the comprehensive risk factors detailed in the company's periodic reports available on their SEDAR+ profile, accessible through the www.sedarplus.ca platform. As Helix continues to shape what it describes as "a near future where today's hard-to-treat cancers are vincible," these financial disclosures provide essential context for understanding the company's progress toward bringing near-term solutions to patients facing some of oncology's most challenging diagnoses while maintaining transparency with the investment community through established regulatory channels.